Asprius Lifesciences develops drug for Diabetic Neuropathy, files patent

economictimes.indiatimes.com:

Asprius Lifesciences has announced that it has developed treatment for Diabetic Neuropathy, a condition that results in nerve damage in peripheral areas of the body. The company said it has already filed a patent for the Fixed-Dose Combination (FDC) that holds promise in treating peripheral neuropathy, a prevalent condition affecting over 2 per cent of the global population. Speaking about the development of the drug, Asprius Lifesciences' Chairman and Managing Director, Vishal Zinzuwadia said: «Our focus has always been on fostering innovation to develop groundbreaking pharma products.

Our goal is to empower the medical fraternity and enhance patient treatment, particularly when conventional therapies fall short. By actively addressing medical conditions that increase the risk of neuropathy development and introducing neuro-protective medications, the company aims to support early neuronal regeneration and minimize the impact of the condition.» Dr. Sanjay Agrawal, the company's medical director said that there is an urgency of addressing the Diabetic Neuropathy scenario in the country.

«India has a high prevalence of diabetes, with an estimated 77 million adults living with the disease, projected to rise to 101.2 million by 2030. Type 2 diabetes accounts for about 90-95% of all cases in India and is often associated with lifestyle factors such as poor diet, sedentary lifestyle, and obesity. It is high time we addressed this prevalent condition, especially as Diabetic Neuropathy can cause damage to specific subdivisions of the nervous system.» Dr.